ClinicalTrials.gg
CompletedNCT00103662Updated Mar 13, 2014Results posted

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

A Phase 3 interventional study of Granulocyte colony-stimulating factor plus plerixafor and Granulocyte colony-stimulating factor plus placebo in Multiple Myeloma, sponsored by Genzyme, a Sanofi Company. Completed at 39 sites in 3 countries. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2014-03-13.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma — 1 open to participants now, 1 under way, 1 of them phase 3. Granulocyte Colony-Stimulating Factor · Multiple Myeloma.

Enrollment
2nd of 28
302 · median 38
Started
2005
with 4 others
Phase 3
2 of 28
1 open now
Registered
3rd of 28
by date
Lead sponsor
7 of 28
Genzyme, a Sanofi Company

Among the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, this one is the 2nd largest by enrollment, is one of 5 that started in 2005, is one of 2 in phase 3, and was the 3rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

1 of the 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing Granulocyte Colony-Stimulating Factor in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in multiple myeloma patients for autologous transplantation.

Read the detailed description

A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Currently filgrastim (G-CSF), a colony stimulating factor, is used to cause the growth and mobilization of stem cells from bone marrow to peripheral blood, which can then be collected from the peripheral blood by a process called apheresis. Plerixafor aids in the release of the stem cells from the bone marrow into the peripheral blood, possibly allowing for a more rapid collection of a larger number of stem cells from the peripheral blood. Larger stem cell doses for transplantation correlate to faster recovery times after high dose chemotherapy followed with stem cell transplantation. This study is intended to determine whether the combination of plerixafor with filgrastim (G-CSF)is better than filgrastim (G-CSF) alone in helping multiple myeloma patients collect at least 6 million stem cells in two or less apheresis sessions.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of multiple myeloma in first or second complete or partial remission
  • >= 4 weeks since last cycle of chemotherapy (thalidomide, dexamethasone, and Velcade were not considered prior chemotherapy for the purpose of this study)
  • Recovered from all acute toxic effects of prior chemotherapy
  • (ECOG) performance status of 0 or 1
  • White Blood Cell count (WBC) > 2.5*10\^9/L
  • Absolute polymorphonuclear leukocytes (PMN) count > 1.5*10\^9/L
  • (PLT) > 100*10\^9/L
  • Serum creatinine \<=2.2 mg/dL
  • Cardiac and pulmonary status sufficient to undergo apheresis and transplantation
  • Negative for

Exclusion criteria

Exclusion Criteria):

  • Failed previous stem cell collection
  • Previous stem cell transplantation
  • or myelomatous meningitis
  • Radiation to ≥ 50% of the pelvis
  • Abnormal (ECG) with rhythm disturbance (ventricular arrhythmias) or other conduction abnormality
  • Received bone-seeking radionuclides (e.g. holmium)
  • A residual acute medical condition resulting from prior chemotherapy
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    G-CSF plus plerixafor

    Drug: Granulocyte colony-stimulating factor plus plerixafor

  • Placebo comparator
    G-CSF plus placebo

    Drug: Granulocyte colony-stimulating factor plus placebo

Interventions

  • DrugGranulocyte colony-stimulating factor plus plerixafor

    Drug pages: Granulocyte Colony-Stimulating Factor · Plerixafor

    Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.

    Also known as: Mozobil, AMD3100

  • DrugGranulocyte colony-stimulating factor plus placebo

    Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis.

    Proportion of participants achieving a target of ≥ 6\*10\^6 CD34+ cells/kg in 2 or fewer days of apheresis. Central lab data were taken from Days 5 to 6 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 2 apheresis days.

    Time frame: up to Day 6

Secondary outcomes

  1. Number of Participants With Adverse Events

    Number of participants with treatment emergent adverse events (AEs). The timeframe for treatment emergent AEs is defined as Day 1 (start of G-CSF Mobilization) to the day before starting chemotherapy (approximately 38 days later). AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale. AEs of Grade 3 were considered severe and Grade 4 were considered life-threatening.

    Time frame: up to Day 38

  2. Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 4 or Fewer Days of Apheresis.

    Proportion of participants achieving a target of ≥ 6\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.

    Time frame: up to Day 8

  3. Proportion of Participants Achieving a Target of ≥ 2*10^6 CD34+ Cells/kg in 4 or Fewer Days of Apheresis.

    Proportion of participants achieving a target of ≥ 2\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.

    Time frame: up to Day 8

  4. Median Number of Days to ≥6*10^6 CD34+ Cells/kg

    The Kaplan Meier estimate of median number of days (number of days at which 50% of participants have experienced the event, accounting for censored values) in each treatment arm to collect an optimum number of cells (≥6\*10\^6 CD34+ cells/kg) for transplantation.

    Time frame: up to Day 8

  5. Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment

    The Kaplan Meier estimate of median number of days to PMN engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met and was evaluated up to 12 months post transplant.

    Time frame: Up to Month 13

  6. Median Number of Days to Platelet (PLT) Engraftment

    The Kaplan Meier estimate of median number of days to PLT engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as ≥ 20\*10\^9/L without transfusion for the preceding 7 days. Time to engraftment corresponded to the first day that the criteria were met and was evaluated up to 12 months post transplant.

    Time frame: Up to Month 13

  7. Graft Durability at 100 Days Post Transplantation

    The proportion of participants maintaining a durable graft at 100 days post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

    Time frame: approximately Day 138

  8. Graft Durability at 6 Months Post Transplantation

    The proportion of participants maintaining a durable graft at 6 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

    Time frame: approximately Month 7

  9. Graft Durability at 12 Months Post Transplantation

    The proportion of participants maintaining a durable graft at 12 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

    Time frame: approximately Month 13

07

Results

Posted Sep 29, 2010

Participant flow

Participants with multiple myeloma (MM) eligible for autologous hematopoietic stem cell transplant were recruited from 40 centers (38 in the U.S., 1 in Germany, 1 in Canada). The first participant was randomized on 04 February 2005 and the last participant's last study visit occurred on 22 January 2008. A total of 302 participants were randomized.

Participant flow — Overall Study
MilestoneG-CSF Plus PlerixaforG-CSF Plus Placebo
Started148154
Completed129121
Not completed1933
Withdrew: Entered rescue procedure07
Withdrew: Death77
Withdrew: Elective withdrawal55
Withdrew: Lost to follow-up01
Withdrew: Other69
Withdrew: Failed mobilization04
Withdrew: Intercurrent illness10

Outcome measures

PrimaryProportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis.

Proportion of participants achieving a target of ≥ 6\*10\^6 CD34+ cells/kg in 2 or fewer days of apheresis. Central lab data were taken from Days 5 to 6 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 2 apheresis days.

Time frame:
up to Day 6
Reported as:
Number · proportion of participants
Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 2 or Fewer Days of Apheresis.
proportion of participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Proportion achieving target in ≤2 days0.7160.344
Proportion not achieving target in ≤2 days0.2840.656
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment emergent adverse events (AEs). The timeframe for treatment emergent AEs is defined as Day 1 (start of G-CSF Mobilization) to the day before starting chemotherapy (approximately 38 days later). AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale. AEs of Grade 3 were considered severe and Grade 4 were considered life-threatening.

Time frame:
up to Day 38
Reported as:
Number · participants
Number of Participants With Adverse Events
participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Adverse Events (AEs)140140
Related AEs9567
AEs Leading to early treatment termination12
AEs Leading to early termination30
Grade 3 (severe) or 4 (life-threatening) AEs1111
Serious Adverse Events (SAEs)46
SecondaryProportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 4 or Fewer Days of Apheresis.

Proportion of participants achieving a target of ≥ 6\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.

Time frame:
up to Day 8
Reported as:
Number · proportion of participants
Proportion of Participants Achieving a Target of ≥ 6*10^6 CD34+ Cells/kg in 4 or Fewer Days of Apheresis.
proportion of participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Proportion achieving target in ≤4 days0.7570.513
Proportion not achieving target in ≤4 days0.2430.487
SecondaryProportion of Participants Achieving a Target of ≥ 2*10^6 CD34+ Cells/kg in 4 or Fewer Days of Apheresis.

Proportion of participants achieving a target of ≥ 2\*10\^6 CD34+ cells/kg in 4 or fewer days of apheresis. Central lab data were taken from Days 5 to 8 of the Treatment/Apheresis period. Each participant's value was calculated as the sum of all daily values collected over the 4 apheresis days.

Time frame:
up to Day 8
Reported as:
Number · proportion of participants
Proportion of Participants Achieving a Target of ≥ 2*10^6 CD34+ Cells/kg in 4 or Fewer Days of Apheresis.
proportion of participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Proportion achieving target in ≤4 days0.9530.883
Proportion not achieving target in ≤4 days0.0470.117
SecondaryMedian Number of Days to ≥6*10^6 CD34+ Cells/kg

The Kaplan Meier estimate of median number of days (number of days at which 50% of participants have experienced the event, accounting for censored values) in each treatment arm to collect an optimum number of cells (≥6\*10\^6 CD34+ cells/kg) for transplantation.

Time frame:
up to Day 8
Reported as:
Median · Days
Median Number of Days to ≥6*10^6 CD34+ Cells/kg
DaysG-CSF Plus PlerixaforG-CSF Plus Placebo
Median Number of Days to ≥6*10^6 CD34+ Cells/kg1.0 (1.0 to 2.0)4.0 (2.0 to NA)
SecondaryMedian Number of Days to Polymorphonuclear (PMN) Cell Engraftment

The Kaplan Meier estimate of median number of days to PMN engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as PMN counts ≥ 0.5\*10\^9/L for 3 consecutive days or ≥ 1.0\*10\^9/L for 1 day. Time to engraftment corresponded to the first day that the criteria were met and was evaluated up to 12 months post transplant.

Time frame:
Up to Month 13
Reported as:
Median · Days
Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment
DaysG-CSF Plus PlerixaforG-CSF Plus Placebo
Median Number of Days to Polymorphonuclear (PMN) Cell Engraftment11.0 (10.0 to 12.0)11.0 (11.0 to 12.0)
SecondaryMedian Number of Days to Platelet (PLT) Engraftment

The Kaplan Meier estimate of median number of days to PLT engraftment (number of days at which 50% of participants have experienced the event, accounting for censored values) was a secondary efficacy endpoint. Engraftment was defined as ≥ 20\*10\^9/L without transfusion for the preceding 7 days. Time to engraftment corresponded to the first day that the criteria were met and was evaluated up to 12 months post transplant.

Time frame:
Up to Month 13
Reported as:
Median · Days
Median Number of Days to Platelet (PLT) Engraftment
DaysG-CSF Plus PlerixaforG-CSF Plus Placebo
Median Number of Days to Platelet (PLT) Engraftment18.0 (16.0 to 22.0)18.0 (16.0 to 21.0)
SecondaryGraft Durability at 100 Days Post Transplantation

The proportion of participants maintaining a durable graft at 100 days post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

Time frame:
approximately Day 138
Reported as:
Number · proportion of participants
Graft Durability at 100 Days Post Transplantation
proportion of participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Proportion of participants with a durable graft0.9860.978
Proportion of participants without a durable graft0.0140.022
SecondaryGraft Durability at 6 Months Post Transplantation

The proportion of participants maintaining a durable graft at 6 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

Time frame:
approximately Month 7
Reported as:
Number · proportion of participants
Graft Durability at 6 Months Post Transplantation
proportion of participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Proportion of participants with a durable graft0.9850.984
Proportion of participants without a durable graft0.0150.016
SecondaryGraft Durability at 12 Months Post Transplantation

The proportion of participants maintaining a durable graft at 12 months post-transplantation by at least 2 of the following criteria (without erythropoietin (EPO), G-CSF, or transfusions): (1) a platelet count \>50000/µL without transfusion for at least 2 weeks, (2) hemoglobin \>=10g/dL for at least 1 month, (3) and absolute neutrophil count \>1000/µL for at least 1 week.

Time frame:
approximately Month 13
Reported as:
Number · proportion of participants
Graft Durability at 12 Months Post Transplantation
proportion of participantsG-CSF Plus PlerixaforG-CSF Plus Placebo
Proportion of participants with a durable graft0.9920.992
Proportion of participants without a durable graft0.0080.008

Adverse events

Collected over Day 1 (start of G-CSF Mobilization plus Treatment/Apheresis) to the day before starting chemotherapy. Chemotherapy typically started within 30 days of the last apheresis (which may have occurred on Day 5, 6, 7, or 8).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
G-CSF Plus Plerixafor—4/147 (2.7%)140/147 (95.2%)
G-CSF Plus Placebo—6/151 (4%)140/151 (92.7%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventG-CSF Plus PlerixaforG-CSF Plus Placebo
NauseaGastrointestinal disorders0/1472/151
Atrial fibrillationCardiac disorders1/1470/151
Bone painMusculoskeletal and connective tissue disorders1/1471/151
HemiparesisNervous system disorders1/1470/151
Deep vein thrombosisVascular disorders1/1470/151
VomitingGastrointestinal disorders0/1471/151
Enterobacter bacteraemiaInfections and infestations0/1471/151
DehydrationMetabolism and nutrition disorders0/1471/151
Muscle spasticityNervous system disorders0/1471/151
AgitationPsychiatric disorders0/1471/151
Most frequent other events
Showing 10 of 245
Most frequent other events
EventG-CSF Plus PlerixaforG-CSF Plus Placebo
Bone painMusculoskeletal and connective tissue disorders53/14764/151
NauseaGastrointestinal disorders51/14739/151
DiarrhoeaGastrointestinal disorders47/14729/151
FatigueGeneral disorders40/14741/151
HeadacheNervous system disorders30/14735/151
Back painMusculoskeletal and connective tissue disorders23/14734/151
ParaesthesiaNervous system disorders33/14734/151
Injection site erythemaGeneral disorders32/1475/151
HypokalaemiaMetabolism and nutrition disorders19/14729/151
Catheter site painGeneral disorders14/14719/151

Baseline characteristics

Age, Continuous
Age, Continuous(years)G-CSF Plus PlerixaforG-CSF Plus PlaceboTotal
Mean58.2 ± 8.458.4 ± 8.658.3 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)G-CSF Plus PlerixaforG-CSF Plus PlaceboTotal
Female484795
Male100107207
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)G-CSF Plus PlerixaforG-CSF Plus PlaceboTotal
Caucasian117128245
African-American181432
Asian134
Hispanic/Latino11415
Other156
08

Study locations

39 sites
  • City of Hope Samaritan Bone Marrow Transplant Program
    Phoenix, Arizona 85006, United States
  • Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • Cedars-Sinai
    Los Angeles, California 90048, United States
  • University of California
    Los Angeles, California 90095, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
  • University of Florida
    Gainesville, Florida 32611, United States
  • H. Lee Moffitt Cancer Center and Research Institute
    Tampa, Florida 33612, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Indiana Blood and Marrow Transplantation Center
    Beech Grove, Indiana 46107, United States
  • University of Iowa Hosptials and Clinics
    Iowa City, Iowa 52242, United States
  • Fairview-University Medical Center, University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Kansas City Cancer Center
    Kansas City, Missouri 64111, United States
  • Washington University School of Medicine, Division of Bone Marrow Transplantation and Leukemia
    Saint Louis, Missouri 63110, United States
  • The Cancer Center at Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • St. Vincent's Comprehensive Cancer Center
    New York, New York 10011, United States
  • New York Hospital
    New York, New York 10032, United States
  • Memorial Sloan Kettering
    New York, New York 10065, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Case Western Reserve University
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Wilford Hall Medical Center
    Lackland AFB, Texas 78236, United States
  • Texas Transplant Institute
    San Antonio, Texas 78229, United States
  • University of Texas Health Science Center
    San Antonio, Texas 78229, United States
  • Utah Blood and Marrow Transplant Program, University of Utah
    Salt Lake City, Utah 84132, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Universitätsklinikum Heidelberg,
    Heidelberg, 69120, Germany
09

References and documents

Publications

  • DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009 Jun 4;113(23):5720-6. doi: 10.1182/blood-2008-08-174946. Epub 2009 Apr 10. PubMed 19363221 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2005, a primary completion of Oct 2006 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2010, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2005
First posted
Feb 14, 2005
Start
Jan 2005
Primary completionActual
Oct 2006
CompletionActual
Jan 2008
Results first posted
Sep 29, 2010
Last update
Mar 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00103662
First posted
Feb 14, 2005
Start date
Jan 2005
Primary completion
Oct 2006
Completion
Jan 2008
Results posted
Sep 29, 2010
Last update
Mar 13, 2014

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor

Start the discussion